Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Prostate cancer updates: Advances in precision medicine and PARP inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.10.19
Views: 3874

Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal

Prof Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs a session with Dr Joaquin Mateo (Vall d’Hebron Institute of Oncology, Barcelona, Spain), Dr Shahneen Sandhu (Peter MacCallum Cancer, Melbourne, Australia) and Prof Bertrand Tombal (Université catholique de Louvain, Brussels, Belgium) on the key developments in prostate cancer that were presented at ESMO 2019.

Prof Tombal provides a summary of the RADICALS trial which investigated the role of radiation therapy in patients with localised disease or biochemical failure.

The panel then discuss the results from the SPARTAN and STAMPEDE trials and question whether docetaxel and androgen receptor targeted agents should be both used upfront.

Dr Sandhu provides an overview of the PROfound trial, in which patients experienced an increased progression-free survival with olaparib. She also describes the results of this study as a game changer for precision medicine.

The panel conclude by discussing the use of PARP inhibitors in the treatment of prostate cancer and share their experiences with using these agents in the clinic.

This programme has been supported by an unrestricted educational grant from AstraZeneca.

Latest data from the RADICALS trial
Results from the SPARTAN trial
Updates from the STAMPEDE trial
Docetaxel vs androgen-receptor targeted agents in the metastatic setting
Radiotherapy for patients with castration-sensitive metastatic disease
Overview of the PROfound trial
PARP inhibitors for the treatment of prostate cancer
Genetic testing in the clinic
Toxicities associated with PARP inhibitors
Summary of the CARD trial


Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation